Tranexamic Acid Is Efficacious at Decreasing the Rate of Blood Loss in Adolescent Scoliosis Surgery: A Randomized Placebo-Controlled Trial.
Susan M Goobie, David Zurakowski, Michael P Glotzbecker...
https://pubmed.ncbi.nlm.nih.gov/30516625/Actively Recruiting
Led by Turku University Hospital · Updated on 2025-05-07
194
Participants Needed
2
Research Sites
N/A
Total Duration
The OCTAGON trial is a randomized, double-blind, multicenter clinical study evaluating the use of pooled human plasma compared to crystalloid fluids in adolescents aged 10 to 21 years undergoing posterior spinal fusion surgery for adolescent idiopathic scoliosis AIS or neuromuscular scoliosis NMS. The study aims to determine if pooled human plasma can reduce intraoperative blood loss and the need for blood transfusions while monitoring safety and quality of life over a minimum two-year follow-up period. Participants are randomly assigned to receive either pooled human plasma Octaplas or a placebo crystalloid solution Plasmalyte as an intravenous infusion of 10 mLkg up to 400 mL over one hour before surgery. The surgery involves spinal fusion using pedicle screws, and standard anesthesia and pain management protocols are followed. The study includes extensive blinding procedures and safety monitoring, including the possibility of unblinding if severe adverse events occur. During the study, participants undergo regular assessments including measurements of blood loss during and after surgery, pain levels, opioid consumption, and quality of life questionnaires at baseline, 6 months, and 24 months post-surgery. Safety evaluations include monitoring for allergic reactions, infections, and other complications. The trial ends 24 months after the last participants surgery, with ongoing data collection and safety oversight by an independent monitoring board.
CONDITIONS
Pooled Human Plasma vs Crystalloid in The Management of Children Undergoing Instrumented Spinal Fusion for Scoliosis
I
Ilkka Helenius, MD, orthopaedic surgeon
T
Tanja Perokorpi, MSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Turku University Hospital
Lead Sponsor
Helsinki University Central Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for eligibility assessments including informed consent and MRI for AIS patients
Duration - Day of surgery
Participants receive either pooled human plasma or crystalloid infusion over 1 hour during anesthesia before scoliosis surgery. Surgery and anesthesia are conducted according to standard procedures while monitoring blood loss and vital signs.
1 visit (in-person) on surgery day including infusion and surgery
Duration - Up to 5 days post-surgery
Participants are monitored in the hospital for up to 5 days after surgery for blood loss, pain management, wound care, and adverse events. Assessments include hemoglobin levels, drain output, pain scores, and opioid use.
Daily hospital visits for postoperative care and assessments
Duration - 24 months
Participants attend outpatient visits at 6 and 24 months after surgery for health-related quality of life assessments, scoliosis radiographs, pain evaluation, and safety monitoring.
2 outpatient visits at 6 and 24 months post-surgery
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Susan M Goobie, David Zurakowski, Michael P Glotzbecker...
https://pubmed.ncbi.nlm.nih.gov/30516625/Linda Helenius, Paul Gerdhem, Matti Ahonen...
https://pubmed.ncbi.nlm.nih.gov/36047026/Linda Helenius, Elias Diarbakerli, Anna Grauers...
https://pubmed.ncbi.nlm.nih.gov/31436653/Venla Soini, Arimatias Raitio, Ilkka Helenius...
https://pubmed.ncbi.nlm.nih.gov/36561891/Matti Ahonen, Ilkka Helenius, Mika Gissler...
https://pubmed.ncbi.nlm.nih.gov/37679048/Fatemeh Javaherforoosh Zadeh, Farahzad Janatmakan, Mohsen Shafaee Tonekaboni...
https://pubmed.ncbi.nlm.nih.gov/31497522/I Helenius, H Keskinen, J Syvänen...
https://pubmed.ncbi.nlm.nih.gov/26920966/Turku University Hospital
Lead Sponsor
Helsinki University Central Hospital
Collaborating Sponsor